Sumitomo Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Sumitomo Pharma şirketinin toplam hissedar öz sermayesi ¥114.2B ve toplam borcu ¥389.4B olup, bu da borç-öz sermaye oranını 340.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥799.8B ve ¥685.5B dir.

Anahtar bilgiler

340.8%

Borç/özkaynak oranı

JP¥389.38b

Borç

Faiz karşılama oranı	n/a
Nakit	JP¥99.08b
Eşitlik	JP¥114.24b
Toplam yükümlülükler	JP¥685.52b
Toplam varlıklar	JP¥799.77b

Son finansal sağlık güncellemeleri

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Nov 25

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Nov 25

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

Sep 12

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Aug 16

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Jun 26

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

May 13

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Apr 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4506 'nin kısa vadeli varlıkları ( ¥311.9B ) kısa vadeli yükümlülüklerini ( ¥484.2B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 4506 şirketinin kısa vadeli varlıkları ( ¥311.9B ) uzun vadeli yükümlülüklerini ( ¥201.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4506 'nin net borç/öz sermaye oranı ( 254.1% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 4506 şirketinin borç/öz sermaye oranı son 5 yılda 5.8% seviyesinden 340.8% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4506 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 4506 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sumitomo Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

New major risk - Share price stability

Second quarter 2025 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to JP¥25.34 loss

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Consensus EPS estimates upgraded to JP¥39.20 loss

Price target increased by 14% to JP¥365

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to JP¥48.57 loss

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Consensus EPS estimates upgraded to JP¥77.85 loss

Consensus EPS estimates upgraded to JP¥103 loss

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings: EPS misses analyst expectations

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

Price target decreased by 18% to JP¥334

Consensus EPS estimates fall by 21%

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Price target decreased by 10% to JP¥413

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Price target decreased by 7.8% to JP¥442

Consensus EPS estimates fall by 23%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

Price target decreased by 9.3% to JP¥510

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 15%

Price target decreased by 11% to JP¥630

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Consensus EPS estimates fall by 14%

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥811

Price target decreased by 7.2% to JP¥883

Consensus EPS estimates fall by 26%, revenue upgraded

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Full year 2023 earnings: EPS misses analyst expectations

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Consensus EPS estimates upgraded to JP¥35.42 loss

Consensus EPS estimates upgraded to JP¥35.42 loss

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Consensus estimates of losses per share improve by 85%

Consensus EPS estimates have been downgraded.

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022)

Mitsui & Co., Ltd. (TSE:8031) agreed to acquire Sumitomo Pharma Animal Health Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).